Multiple Ascending Dose Safety Study of ShK-186 (Dalazatide) in Healthy Volunteers

• ClinicalTrials.gov Identifier: NCT02446340
• Recruitment Status: Completed
• First Posted: May 18, 2015
• Last Update Posted: May 18, 2015
• Sponsor: Kineta Inc.
• Information provided by (Responsible Party): Kineta Inc.

Study Description

Brief Summary:

The purpose of this study is to examine safety outcomes in healthy volunteers after systemic administration of multiple ascending doses of dalazatide.

Condition or disease	Intervention/treatment	Phase
Healthy	Drug: dalazatide; Drug: placebo	Phase 1

Detailed Description:

The purpose of this study is to examine safety outcomes in healthy volunteers after systemic administration of multiple ascending doses of dalazatide delivered via subcutaneous injection twice per week for a total of 9 doses.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 32 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Double (Participant, Investigator)
• Official Title: A Double-Blind, Placebo-Controlled Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of ShK-186
• Study Start Date: November 2013
• Actual Primary Completion Date: April 2014
• Actual Study Completion Date: April 2014

Arms and Interventions

Arm	Intervention/treatment
Experimental: dalazatide 5ug; 8 subjects, 6 given active agent and 2 given placebo	Drug: dalazatide; Different doses of drug, subcutaneous injection twice per week for a total of 9 doses.; Other Name: ShK-186; Drug: placebo; Placebo delivered via subcutaneous administration twice per week for a total of 9 doses; Other Name: Sub Q Placebo
Experimental: dalazatide 15ug; 8 subjects, 6 given active agent and 2 given placebo	Drug: dalazatide; Different doses of drug, subcutaneous injection twice per week for a total of 9 doses.; Other Name: ShK-186; Drug: placebo; Placebo delivered via subcutaneous administration twice per week for a total of 9 doses; Other Name: Sub Q Placebo
Experimental: dalazatide 30ug; 8 subjects, 6 given active agent and 2 given placebo	Drug: dalazatide; Different doses of drug, subcutaneous injection twice per week for a total of 9 doses.; Other Name: ShK-186; Drug: placebo; Placebo delivered via subcutaneous administration twice per week for a total of 9 doses; Other Name: Sub Q Placebo
Experimental: dalazatide 60ug; 8 subjects, 6 given active agent and 2 given placebo	Drug: dalazatide; Different doses of drug, subcutaneous injection twice per week for a total of 9 doses.; Other Name: ShK-186; Drug: placebo; Placebo delivered via subcutaneous administration twice per week for a total of 9 doses; Other Name: Sub Q Placebo

Outcome Measures

Primary Outcome Measures :

1. Subjects with adverse events [ Time Frame: From randomization to Day 57 (14 time points) ]

Secondary Outcome Measures :

1. Subjects with changes in vital signs [ Time Frame: From randomization through Day 57 (14 time points) ]
   Vital signs include temperature, respiratory rate, supine blood pressure and pulse.
2. Subjects with changes in symptom-directed physical examinations [ Time Frame: From date of randomization to day 57 (14 timepoints) ]
3. Subjects with changes in 12-lead electrocardiograms [ Time Frame: From date of randomization to day 57 (5 timepoints) ]
4. PK parameters [ Time Frame: pre-dose, 15 minutes post dose, 30 minutes post dose, 1 hour post dose, 2 hours post dose, 4 hours post dose, 8 hours post dose, 12 hours post dose ]
   Parameters include Area under the plasma concentration versus time curve of dalazatide (AUC)
5. Presence of specific anti-drug antibody [ Time Frame: From date of randomization through Day 57 (4 timepoints). ]
   Serum evaluated for specific anti-drug antibody using ELISA-based immunoassay.

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 45 Years (Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

1. healthy normal male and female subjects, ages 18 to 45, inclusive;
2. able to communicate and able to provide valid, written informed consent;
3. within the body mass index (BMI) range of approximately 18.0 to 30.0 kg/m2, inclusive;
4. minimum weight of 50 kg;
5. willingness to remain totally abstinent or use adequate contraception; e.g., 2 of the following methods: hormonal contraceptive, intrauterine device, condom, diaphragm, and spermicidal gel/foam) in order to prevent pregnancy from the screening visit until 60 days after the follow-up visit. For men, the donation of sperm during this period is also prohibited.

Exclusion Criteria:

1. the presence of clinically significant medical history as determined by the investigator.
2. the history of clinically significant cardiac abnormalities or presence of clinically significant abnormality on 12-lead ECG.
3. the history of pre-existing paresthesia or neuropathy;
4. abnormalities on neurologic exam at screening or baseline
5. the history of any cancer requiring systemic chemotherapy or radiation; individuals with a history of non-melanoma skin cancer, nonrecurring carcinoma in situ treated with laser or cryotherapy or cervical cancer-in-situ, resected surgically with no evidence of disease, may be accepted on a case by case basis at the discretion of the Investigator;
6. the presence of acute infection or history of acute infection within 7 days prior to receipt of the study drug; additionally, oral temperature may not exceed 37.4°C at baseline;
7. the presence of clinically significant laboratory abnormalities (chemistry panel of 20 analytes [Chem-20; fasted 10-12 hours], complete blood count [CBC], and urinalysis [UA]) as determined by the investigator;
8. positive urine drug screen for drugs of abuse (opiates, methadone, cocaine, amphetamines, cannabinoids, barbiturates, benzodiazepines, cotinine, tricyclic antidepressants and alcohol) at Screening or at Baseline.
9. typical intake of more than 7 units of alcohol per week (one unit of alcohol equals approximately 250 mL of beer, 100 mL of wine or 35 mL of spirits)
10. a positive hepatitis screen (Hepatitis BsAg or anti-HCV) or positive Human Immunodeficiency Virus (HIV) antibody test ;
11. a history of multiple drug allergies that are important in the view of the Investigator;
12. any history of anaphylaxis or a history of allergy to a medication, diet, or environmental exposure (including bee stings) that are important in the view of the Investigator;
13. participation in another clinical trial with receipt of an investigational product within 60 days of dose administration (or 5 half lives, whichever is longer);
14. recent (within 1 year of Screening) history of illicit drug use;
15. history of alcohol abuse that is important in the view of the Investigator
16. inadequate venous access that would interfere with obtaining blood samples;
17. use of prescription medications, over the counter products, herbal remedies and nutritional supplements within 7 days of study drug administration and throughout the study, or the anticipated need for prescription medications prior to Study Completion;
18. recipients of blood transfusion or transfusion of blood or plasma products within 60 days of study drug administration;
19. donation of blood > 500 mL within 2 months of study drug administration;
20. positive pregnancy test at screening or at baseline (female subjects only);
21. history within the past 3 months of eating disorders or other conditions which may lead to suspicion about the participant's nutritional status;
22. inability or unwillingness to comply with study restrictions

Contacts and Locations

Locations

United States, Kansas

PRA International

Lenexa, Kansas, United States, 66219

Sponsors and Collaborators

Kineta Inc.

Investigators

• Study Chair: Shawn Iadonato, PhD; Kineta Inc.

More Information

• Responsible Party: Kineta Inc.
• ClinicalTrials.gov Identifier: NCT02446340
• Other Study ID Numbers: 186-02
• First Posted: May 18, 2015
• Last Update Posted: May 18, 2015
• Last Verified: May 2015

Keywords provided by Kineta Inc.:

ShK-186; dalazatide; Kv1.3; SHK